{"id":4054,"date":"2016-08-23T09:45:02","date_gmt":"2016-08-23T13:45:02","guid":{"rendered":"https:\/\/medicarereport.org\/?p=4054"},"modified":"2016-08-23T09:45:02","modified_gmt":"2016-08-23T13:45:02","slug":"how-obamas-fda-keeps-generic-drugs-off-the-market","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=4054","title":{"rendered":"How Obama\u2019s FDA keeps generic drugs off the market"},"content":{"rendered":"<p>(By Scott Gottlieb, MD for AEI)<\/p>\n<p>One of the biggest factors fueling the angst over drug prices in the U.S. is that some older medicines that should be sold cheaply as generics are still priced very high, often owing to a dwindling number of generic competitors and the rising cost of producing these drugs. Bernie Sanders and Hillary Clinton like to blame generic-company mergers and greedy drugmakers. But a closer look reveals that a series of regulatory policy blunders is at fault. <a href=\"http:\/\/www.aei.org\/publication\/how-obamas-fda-keeps-generic-drugs-off-the-market\/?utm_source=paramount&amp;utm_medium=email&amp;utm_content=AEITODAY&amp;utm_campaign=082316\" target=\"_blank\">Continue reading article here&#8230;..<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/AEI-LOGO.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-4053\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/AEI-LOGO.png\" alt=\"AEI LOGO\" width=\"131\" height=\"77\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/AEI-LOGO.png 131w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/AEI-LOGO-130x77.png 130w\" sizes=\"auto, (max-width: 131px) 100vw, 131px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Scott Gottlieb, MD for AEI) One of the biggest factors fueling the angst over drug prices in the U.S.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-4054","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4054"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4054\/revisions"}],"predecessor-version":[{"id":4056,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/4054\/revisions\/4056"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}